{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:00:12Z","timestamp":1790200812758,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.cld.2022.03.009","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T21:17:53Z","timestamp":1656105473000},"page":"489-519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Recent Insights into Pediatric Primary Sclerosing Cholangitis"],"prefix":"10.1016","volume":"26","author":[{"given":"James P.","family":"Stevens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitika A.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cld.2022.03.009_bib1","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis. Review","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.03.009_bib2","article-title":"Cutting edge issues in juvenile sclerosing cholangitis. review","author":"Di Giorgio","year":"2021","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1016\/j.cld.2022.03.009_bib3","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.29204","article-title":"The natural history of primary sclerosing cholangitis in 781 children: a multicenter, international collaboration. article","volume":"66","author":"Deneau","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2022.03.009_bib4","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.26454","article-title":"Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. article","volume":"58","author":"Deneau","year":"2013","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.cld.2022.03.009_bib5","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMra1506330","article-title":"Primary sclerosing cholangitis. review","volume":"375","author":"Lazaridis","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2022.03.009_bib6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MPG.0000000000001801","article-title":"Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN hepatology committee position statement. article","volume":"66","author":"Mieli-Vergani","year":"2018","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"4","key":"10.1016\/j.cld.2022.03.009_bib7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S1499-3872(16)60088-7","article-title":"Long-term follow-up of children and adolescents with primary sclerosing cholangitis and autoimmune sclerosing cholangitis. Article","volume":"15","author":"Smolka","year":"2016","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.cld.2022.03.009_bib8","article-title":"The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. article","volume":"1183","author":"Toy","year":"2011","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.cld.2022.03.009_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2020-322362","article-title":"Recent advances in clinical practice: epidemiology of autoimmune liver diseases. article","author":"Trivedi","year":"2021","journal-title":"Gut"},{"issue":"21","key":"10.1016\/j.cld.2022.03.009_bib10","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.3748\/wjg.v26.i21.2768","article-title":"Gut microbiome in primary sclerosing cholangitis: a review. review","volume":"26","author":"Little","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2022.03.009_bib11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41575-019-0125-y","article-title":"Cholangiocyte pathobiology. review","volume":"16","author":"Banales","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2022.03.009_bib12","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis \u2013 a comprehensive review. review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2022.03.009_bib13","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.cgh.2008.03.016","article-title":"Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. article","volume":"6","author":"Bergquist","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2022.03.009_bib14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.gene.6364377","article-title":"Different HLA class II associations in ulcerative colitis patients with and without primary sclerosing cholangitis. article","volume":"8","author":"Karlsen","year":"2007","journal-title":"Genes Immun"},{"issue":"2","key":"10.1016\/j.cld.2022.03.009_bib15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1399-0039.2006.00738.x","article-title":"Primary sclerosing cholangitis is associated with extended HLA-DR3 and HLA-DR6 haplotypes. article","volume":"69","author":"Wiencke","year":"2007","journal-title":"Tissue Antigens"},{"issue":"11","key":"10.1016\/j.cld.2022.03.009_bib16","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/lt.22161","article-title":"Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations. article","volume":"16","author":"Bowlus","year":"2010","journal-title":"Liver Transplant"},{"issue":"5","key":"10.1016\/j.cld.2022.03.009_bib17","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/liv.14831","article-title":"Exome sequencing in patient-parent trios suggests new candidate genes for early-onset primary sclerosing cholangitis. article","volume":"41","author":"Haisma","year":"2021","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.cld.2022.03.009_bib18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jhep.2012.03.031","article-title":"Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. article","volume":"57","author":"Folseraas","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2022.03.009_bib19","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/ng.2616","article-title":"Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. article","volume":"45","author":"Liu","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.cld.2022.03.009_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.728","article-title":"Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. article","volume":"43","author":"Melum","year":"2011","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.cld.2022.03.009_bib21","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.30673","article-title":"The gut-liver axis in primary sclerosing cholangitis: are pathobionts the missing link? Note","volume":"70","author":"O\u2019Hara","year":"2019","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cld.2022.03.009_bib22","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/gutjnl-2016-312533","article-title":"Characterisation of the faecal microbiota in Japanese patients with paediatric-onset primary sclerosing cholangitis. letter","volume":"66","author":"Iwasawa","year":"2017","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.cld.2022.03.009_bib23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","article-title":"The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. article","volume":"66","author":"Kummen","year":"2017","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.cld.2022.03.009_bib24","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/apt.15375","article-title":"Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis. Article","volume":"50","author":"R\u00fchlemann","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.cld.2022.03.009_bib25","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/gutjnl-2015-311004","article-title":"Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Article","volume":"65","author":"Sabino","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cld.2022.03.009_bib26","doi-asserted-by":"crossref","first-page":"598152","DOI":"10.3389\/fimmu.2020.598152","article-title":"Gut microbiome of children and adolescents with primary sclerosing cholangitis in association with ulcerative colitis. article","volume":"11","author":"Cortez","year":"2021","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.cld.2022.03.009_bib27","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1136\/gutjnl-2018-316670","article-title":"Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis. Article","volume":"68","author":"Liao","year":"2019","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.cld.2022.03.009_bib28","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41564-018-0333-1","article-title":"Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. article","volume":"4","author":"Nakamoto","year":"2019","journal-title":"Nat Microbiol"},{"issue":"3","key":"10.1016\/j.cld.2022.03.009_bib29","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/ecco-jcc\/jjv204","article-title":"Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis. article","volume":"10","author":"Kevans","year":"2016","journal-title":"J\u00a0Crohn's Colitis"},{"issue":"7","key":"10.1016\/j.cld.2022.03.009_bib30","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/ecco-jcc\/jjaa021","article-title":"A\u00a0pilot integrative analysis of colonic gene expression, gut microbiota, and immune infiltration in primary sclerosing cholangitis-inflammatory bowel disease: association of disease with bile acid pathways. article","volume":"14","author":"Quraishi","year":"2020","journal-title":"J\u00a0Crohn's Colitis"},{"issue":"2","key":"10.1016\/j.cld.2022.03.009_bib31","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/gutjnl-2016-311915","article-title":"The gut-adherent microbiota of PSC-IBD is distinct to that of IBD. Letter","volume":"66","author":"Quraishi","year":"2017","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.cld.2022.03.009_bib32","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/ecco-jcc\/jju023","article-title":"The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured clostridiales II. article","volume":"9","author":"Rossen","year":"2015","journal-title":"J\u00a0Crohn's Colitis"},{"issue":"4","key":"10.1016\/j.cld.2022.03.009_bib33","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/hep.1840130425","article-title":"Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Article","volume":"13","author":"Lichtman","year":"1991","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2022.03.009_bib34","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/0016-5085(90)90833-M","article-title":"Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Article","volume":"98","author":"Lichtman","year":"1990","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2022.03.009_bib35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/liv.13979","article-title":"Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis. article","volume":"39","author":"Dhillon","year":"2019","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.cld.2022.03.009_bib36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrgastro.2016.154","article-title":"Genetics of primary sclerosing cholangitis and pathophysiological implications. review","volume":"14","author":"Jiang","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"24","key":"10.1016\/j.cld.2022.03.009_bib37","doi-asserted-by":"crossref","first-page":"10343","DOI":"10.1021\/jm501052c","article-title":"G-protein-coupled bile acid receptor 1 (GPBAR1, TGR5) agonists reduce the production of proinflammatory cytokines and stabilize the alternative macrophage phenotype. article","volume":"57","author":"H\u00f6genauer","year":"2014","journal-title":"J\u00a0Med Chem"},{"issue":"4","key":"10.1016\/j.cld.2022.03.009_bib38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.livres.2017.12.002","article-title":"Primary sclerosing cholangitis: a review and update. review","volume":"1","author":"Tabibian","year":"2017","journal-title":"Liver Res"},{"issue":"24","key":"10.1016\/j.cld.2022.03.009_bib39","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.3748\/wjg.14.3781","article-title":"Autoantibodies in primary sclerosing cholangitis. editorial","volume":"14","author":"Hov","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"MAR","key":"10.1016\/j.cld.2022.03.009_bib40","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fimmu.2018.00609","article-title":"Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance. review","volume":"9","author":"Sebode","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.cld.2022.03.009_bib41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaut.2013.06.013","article-title":"Mucosal immunity in liver autoimmunity: a comprehensive review. review","volume":"46","author":"Trivedi","year":"2013","journal-title":"J\u00a0Autoimmun"},{"issue":"6","key":"10.1016\/j.cld.2022.03.009_bib42","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.bpg.2011.10.009","article-title":"Pathogenesis of primary sclerosing cholangitis. article","volume":"25","author":"Pollheimer","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2022.03.009_bib43","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.04.003","article-title":"Loss of CD28 expression by liver-infiltrating T\u00a0cells contributes to pathogenesis of primary sclerosing cholangitis. article","volume":"147","author":"Liaskou","year":"2014","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2022.03.009_bib44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1189\/jlb.5A1015-469R","article-title":"CD4+ T\u00a0cells from patients with primary sclerosing cholangitis exhibit reduced apoptosis and down-regulation of proapoptotic Bim in peripheral blood. Article","volume":"101","author":"Schoknecht","year":"2017","journal-title":"J\u00a0Leukoc Biol"},{"issue":"3","key":"10.1016\/j.cld.2022.03.009_bib45","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/hep.26447","article-title":"Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis. article","volume":"58","author":"Katt","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2022.03.009_bib46","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1007\/s10620-012-2511-y","article-title":"Circulating CD4+CD25+ regulatory T\u00a0cells in the pathobiology of ulcerative colitis and concurrent primary sclerosing cholangitis. article","volume":"58","author":"Kekilli","year":"2013","journal-title":"Dig Dis Sci"},{"issue":"12","key":"10.1016\/j.cld.2022.03.009_bib47","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.4049\/jimmunol.1800711","article-title":"Colitis promotes a pathological condition of the liver in the absence of Foxp3\u00a0+ regulatory T\u00a0cells. article","volume":"201","author":"Mathies","year":"2018","journal-title":"J\u00a0Immunol"},{"issue":"8","key":"10.1016\/j.cld.2022.03.009_bib48","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1053\/j.gastro.2018.02.019","article-title":"Alterations in intestinal microbiota lead to production of interleukin 17 by intrahepatic \u03b3\u03b4 T-cell receptor\u2013positive cells and pathogenesis of cholestatic liver disease. article","volume":"154","author":"Tedesco","year":"2018","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2022.03.009_bib49","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jhep.2016.09.002","article-title":"Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease. article","volume":"66","author":"Henriksen","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2022.03.009_bib50","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1089\/jir.2013.0075","article-title":"Differential serum levels of eosinophilic eotaxins in primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis. article","volume":"34","author":"Landi","year":"2014","journal-title":"J\u00a0Interferon Cytokine Res"},{"issue":"2","key":"10.1016\/j.cld.2022.03.009_bib51","first-page":"124","article-title":"Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence. Review","volume":"32","author":"Mertz","year":"2019","journal-title":"Ann Gastroenterol"},{"issue":"11","key":"10.1016\/j.cld.2022.03.009_bib52","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/hep4.1251","article-title":"Gamma glutamyltransferase reduction is associated with favorable outcomes in pediatric primary sclerosing cholangitis. article","volume":"2","author":"Deneau","year":"2018","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.cld.2022.03.009_bib53","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/hep.31560","article-title":"Oral vancomycin, ursodeoxycholic acid, or no therapy for pediatric primary sclerosing cholangitis: a matched analysis. article","volume":"73","author":"Deneau","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2022.03.009_bib54","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/hep.31393","article-title":"The sclerosing cholangitis outcomes in pediatrics (SCOPE) index: a prognostic tool for children. article","volume":"73","author":"Deneau","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2022.03.009_bib55","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1097\/MPG.0000000000002522","article-title":"Assessing the validity of adult-derived prognostic models for primary sclerosing cholangitis outcomes in children. article","volume":"70","author":"Deneau","year":"2020","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"1","key":"10.1016\/j.cld.2022.03.009_bib56","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/gut.2004.046615","article-title":"PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. article","volume":"54","author":"Loftus","year":"2005","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.cld.2022.03.009_bib57","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.cgh.2019.08.048","article-title":"Primary sclerosing cholangitis in children with inflammatory bowel diseases is associated with milder clinical activity but more frequent subclinical inflammation and growth impairment. article","volume":"18","author":"Ricciuto","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2022.03.009_bib58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-2008-1040420","article-title":"Relationship of inflammatory bowel disease and primary sclerosing cholangitis. article","volume":"11","author":"Fausa","year":"1991","journal-title":"Semin Liver Dis"},{"issue":"6","key":"10.1016\/j.cld.2022.03.009_bib59","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/j.1600-6143.2006.01333.x","article-title":"Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. article","volume":"6","author":"Verdonk","year":"2006","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.cld.2022.03.009_bib60","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3109\/00365529709025107","article-title":"Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. article","volume":"32","author":"Rasmussen","year":"1997","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2022.03.009_bib61","first-page":"296","article-title":"Pediatric \"PSC-IBD\": a descriptive report of associated inflammatory bowel disease among pediatric patients with PSC. article","volume":"33","author":"Faubion","year":"2001","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"4","key":"10.1016\/j.cld.2022.03.009_bib62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11894-018-0620-2","article-title":"The IBD and PSC phenotypes of PSC-IBD. Review","volume":"20","author":"Ricciuto","year":"2018","journal-title":"Curr Gastroenterol Rep"},{"issue":"7","key":"10.1016\/j.cld.2022.03.009_bib63","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.cgh.2018.01.020","article-title":"Symptoms do not correlate with findings from colonoscopy in children with inflammatory bowel disease and primary sclerosing cholangitis. article","volume":"16","author":"Ricciuto","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2022.03.009_bib64","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MPG.0000000000001531","article-title":"Unique inflammatory bowel disease phenotype of pediatric primary sclerosing cholangitis: a single-center study. article","volume":"65","author":"Shiau","year":"2017","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"6","key":"10.1016\/j.cld.2022.03.009_bib65","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1055\/s-0043-107029","article-title":"Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) clinical guideline. review","volume":"49","author":"Aabakken","year":"2017","journal-title":"Endoscopy"},{"issue":"5","key":"10.1016\/j.cld.2022.03.009_bib66","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG clinical guideline: primary sclerosing cholangitis. article","volume":"110","author":"Lindor","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.cld.2022.03.009_bib67","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. article","volume":"152","author":"Weism\u00fcller","year":"2017","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2022.03.009_bib68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11894-010-0104-5","article-title":"Sclerosing cholangitis: pediatric perspective. review","volume":"12","author":"Kerkar","year":"2010","journal-title":"Curr Gastroenterol Rep"},{"issue":"6","key":"10.1016\/j.cld.2022.03.009_bib69","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/MPG.0000000000001368","article-title":"The natural history of primary sclerosing cholangitis in children: a large single-center longitudinal cohort study. article","volume":"63","author":"Valentino","year":"2016","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"4","key":"10.1016\/j.cld.2022.03.009_bib70","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1053\/j.gastro.2008.01.042","article-title":"The natural history of small-duct primary sclerosing cholangitis. article","volume":"134","author":"Bj\u00f6rnsson","year":"2008","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.cld.2022.03.009_bib71","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s00247-008-0918-6","article-title":"Primary sclerosing cholangitis in children: utility of magnetic resonance cholangiopancreatography. article","volume":"38","author":"Chavhan","year":"2008","journal-title":"Pediatr Radiol"},{"issue":"6","key":"10.1016\/j.cld.2022.03.009_bib72","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00247-001-0617-z","article-title":"Magnetic resonance cholangiopancreatography in primary sclerosing cholangitis in children. article","volume":"32","author":"Ferrara","year":"2002","journal-title":"Pediatr Radiol"},{"issue":"5","key":"10.1016\/j.cld.2022.03.009_bib73","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/j.1572-0241.2003.07401.x","article-title":"Is there a role for liver biopsy in primary sclerosing cholangitis? article","volume":"98","author":"Burak","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2022.03.009_bib74","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2021.07.046","article-title":"Defining primary sclerosing cholangitis: results from an international primary sclerosing cholangitis study group\u00a0consensus process","author":"Ponsioen","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2022.03.009_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2021.07.047","article-title":"Sclerosing cholangitis in pediatric inflammatory bowel disease: early diagnosis and management affect clinical outcome. Article","author":"Hensel","year":"2021","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.cld.2022.03.009_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31893","article-title":"Human leukocyte antigen profile predicts severity of autoimmune liver disease in children of European ancestry. Article","author":"Ma","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2022.03.009_bib77","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1053\/jhep.2001.22131","article-title":"Autoimmune hepatitis\/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. article","volume":"33","author":"Gregorio","year":"2001","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2022.03.009_bib78","doi-asserted-by":"crossref","first-page":"95","DOI":"10.33590\/emjhepatol\/10313935","article-title":"Overlap syndrome with autoimmune hepatitis and primary sclerosing cholangitis","volume":"7","author":"Nayagam","year":"2019","journal-title":"EMJ Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2022.03.009_bib79","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis. article","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2022.03.009_bib80","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2011.11.030","article-title":"Validation and modification of simplified diagnostic criteria for autoimmune hepatitis in children. article","volume":"10","author":"Mileti","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2022.03.009_bib81","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/MEG.0b013e3283554bbf","article-title":"Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. review","volume":"24","author":"Chapman","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2022.03.009_bib82","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/hep.27191","volume":"60","author":"Squires","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2022.03.009_bib83","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1053\/jhep.2003.50289","article-title":"Primary sclerosing cholangitis in children: a long-term follow-up study. Article","volume":"38","author":"Feldstein","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.03.009_bib84","article-title":"Outcome and survival in childhood onset autoimmune sclerosing cholangitis and autoimmune hepatitis: a 13-year follow up study","volume":"46","author":"Scalori","year":"2007","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2022.03.009_bib85","doi-asserted-by":"crossref","DOI":"10.1007\/s11894-015-0438-0","article-title":"Screening for malignancy in primary sclerosing cholangitis (PSC). review","volume":"17","author":"Khaderi","year":"2015","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.cld.2022.03.009_bib86","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jpeds.2021.02.069","article-title":"African American pediatric liver transplant recipients have an increased risk of death after transferring to adult healthcare. article","volume":"233","author":"Katz","year":"2021","journal-title":"J\u00a0Pediatr"},{"issue":"11","key":"10.1016\/j.cld.2022.03.009_bib87","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/hep4.1421","article-title":"A\u00a0prospective trial of withdrawal and reinstitution of ursodeoxycholic acid in pediatric primary sclerosing cholangitis. article","volume":"3","author":"Black","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cld.2022.03.009_bib88","article-title":"Bile acids for primary sclerosing cholangitis. review","volume":"1","author":"Poropat","year":"2011","journal-title":"Cochrane database Syst Rev (Online)"},{"issue":"3","key":"10.1016\/j.cld.2022.03.009_bib89","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. article","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2022.03.009_bib90","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/17474124.2021.1860751","article-title":"Recent advances in the treatment of primary sclerosing cholangitis. review","volume":"15","author":"Bj\u00f6rnsson","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2022.03.009_bib91","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. article","volume":"67","author":"Fickert","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2022.03.009_bib92","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.12232","article-title":"Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. article","volume":"37","author":"Tabibian","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.cld.2022.03.009_bib93","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","article-title":"A\u00a0triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study. article","volume":"25","author":"Rahimpour","year":"2016","journal-title":"J\u00a0Gastrointest Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2022.03.009_bib94","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MPG.0b013e31816fee95","article-title":"Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. article","volume":"47","author":"Davies","year":"2008","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"8","key":"10.1016\/j.cld.2022.03.009_bib95","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/00365521.2020.1787501","article-title":"Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis. article","volume":"55","author":"Ali","year":"2020","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"10.1016\/j.cld.2022.03.009_bib96","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial. article","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2022.03.009_bib97","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jpeds.2019.11.028","article-title":"Seamless management of juvenile autoimmune liver disease: long-term medical and social outcome. article","volume":"218","author":"Di Giorgio","year":"2020","journal-title":"J\u00a0Pediatr"},{"issue":"1","key":"10.1016\/j.cld.2022.03.009_bib98","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jhep.2009.02.024","article-title":"Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. Article","volume":"51","author":"Aw","year":"2009","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2022.03.009_bib99","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A\u00a0randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. Article","volume":"73","author":"Kowdley","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2022.03.009_bib100","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. article","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2022.03.009_bib101","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/hep.30085","article-title":"Primary sclerosing cholangitis risk estimate tool (PREsTo) predicts outcomes of the disease: a derivation and validation study using machine learning","volume":"71","author":"Eaton","year":"2020","journal-title":"Hepatology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932612200023X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932612200023X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:58:45Z","timestamp":1761069525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108932612200023X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S108932612200023X"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2022.03.009","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent Insights into Pediatric Primary Sclerosing Cholangitis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2022.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}